Physician profile
Kimberly L Smith
NPI 1619130200
$5,018.03
in general payments reported to CMS, 2019-2025
39 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $774 · 2021: $697 · 2022: $440 · 2023: $901 · 2024: $656 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.05 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.51 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $646.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $624.75 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $529.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $360.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $304.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.98 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $254.62 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $150.94 | 2022-2025 | Rexulti |
| Amgen INC. | $147.67 | 2019-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceuticals, INC. | $108.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.18 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $84.98 | 2019-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.98 | 2023-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $80.34 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.